The ongoing Phase I trial LuCa-MERIT-1 (NCT05142189) is assessing the safety and efficacy of the BNT116 mRNA vaccine in NSCLC patients with PD-L1 expression > 50% who progressed after PD-1 inhibitor therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.